EARS-Net Belgium Data call for 2016: Instructions for participating laboratories, including data definition. (version 4, 20/3/2017)
|
|
- Lora Morton
- 6 years ago
- Views:
Transcription
1 EARS-Net Belgium Data call for 2016: Instructions for participating laboratories, including data definition. (version 4, 20/3/2017) Questions on this document can be directed towards: Karl Mertens Scientific Institute for Public Health (WIV-ISP) Rue Juliette Wytsmanstraat Brussels Tel , 1
2 Introduction This document gives instructions to laboratories within Belgium to submit data for 2016 to the European Antimicrobial Resistance Surveillance Network (EARS-Net). EARS-Net is the main EU epidemiologic surveillance system for Anti-Microbial Resistance (AMR), and data reported from the network serve as important indicators on the occurrence and spread of AMR in European countries (Ref 1). On a yearly basis, EARS-Net collects and reports across European countries data on AMR against relevant agents within commonly occurring pathogens isolated from clinical invasive samples in humans. National data collection and submitting to EU for BE is organized by the Healthcare-associated infections and antimicrobial resistance service of the Scientific Institute of Public Health (IPH/NSIH, Brussels, BE). Participation to EARS-Net BE for the year 2016 is voluntary. This document relies on the standards and definitions that are laid out by EARS-Net (Ref 2) and summarizes these for participating laboratories. Differences with previous versions of the annual EARS- Net data call for BE are as follows: Addition of objectives; Addition of case definition for AMR and inclusion criteria for tests, samples, isolates; Addition of Data definition following the one of EARS-Net; Removal of the MS Excel template for submitting data, this is replaced by general instructions on the file format and description of variables and code values. Addition of procedure for submitting EARS-Net data by national reference laboratories; Addition of procedure for External Quality Assessment. EARS-Net Case definition for AMR and inclusion criteria EARS-Net uses the following case definition for AMR (see Ref 2 pages for full details). The bacterial species under surveillance are Streptococcus pneumonia (STRPNE), Staphylococcus aureus (STAAUR), Enterococcus faecalis (ENCFAE), Enterococcus faecium (ENCFAI), Escherichia coli (ESCCOL), Klebsiella pneumonia (KLEPNE), Pseudomonas aeruginosa (PSEAER), Acinetobacter spp (ACISPP). All isolates from blood (STRPNE, STAAUR, ENCFAE, ENCFAI, ESCCOL, KLEPNE, PSEAER, ACISPP) and/or cerebrospinal fluid (STRPNE, ESCCOL, KLEPNE, PSEAER, ACISPP), for which a susceptibility test has been performed, have to be included. A pathogen is defined as clinically susceptible, clinically intermediate or clinically resistant to an antibiotic agent according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST, Ref 3) clinical breakpoints, i.e. clinical MIC breakpoints and their inhibition zone diameter correlates. Although EARS-Net encourages the use of EUCAST clinical breakpoints, laboratories using other guidelines are still welcome to submit data if the use of clinical guidelines is specified on the level of the AMR test (variable 37 ReferenceGuidelinesSIR of Table 3). The combinations of microorganisms x sample types x AMR tests that should be included in EARS-Net data are given in Table 1, these 2
3 combinations serve the full set of microorganism/antimicrobial group combinations that are under regular surveillance by EARS-Net as displayed in Table 2. Following the above case definition for AMR, the participating laboratory should prepare and submit annual EARS-Net data for 2016 in the form of an electronic data file in which each individual observation holds info on a particular isolate x sample x AMR test result on a sample that was taken in All results belonging to a combination of isolates (pathogens), sample types and AMR tests given in Table 1 should be submitted. Next to these AMR tests, see also variables 20, 21, 22, 23, 24 of Table 3 collecting supplementary info on confirmation tests for selected pathogens. All laboratories in BE that performed AMR susceptibility tests corresponding to the above defined sample types, isolates and AMR tests are invited to participate. EARS-Net defines no other inclusion criteria besides the ones of the two previous paragraphs. Importantly, no restrictions are placed on the type of patients to include. te however that several variables are collected describing sample and patient characteristics such as a patient s hospitalization status or the ward in the hospital in which a sample was taken (see variables 15, 16, 17, 19 of Table 3). EARS-Net data definition The data file of a particular laboratory will contain variables on the isolate and AMR test level. That is, it will include the info on a particular AMR test as a separate observation, and repeat all info on the level of the isolate over all included AMR tests. Tables 3 and 4 give the data collection definition for isolate and AMR test info, respectively. Variables are numbered and named according to the EARS-Net reporting protocol (Ref 2). Sometimes, old variable names are given as well. Participating laboratories should only submit data on variables for which information can be collected and submitted. Variables 7 (sample date), 9 (laboratory code), 10 (sample type), 11 (patient id), 18 (pathogen), 25 (AMR test) and 26 (test result) are mandatory variables (= Yes ), files without at least these variables cannot be processed by IPH/NSIH. Next to these mandatory variables, other variables are labeled recommended (=, but recommended ) because they contain important characteristics of the patient or the hospital stay if the sample was taken in a hospital. The rest of the variables in Tables 3 and 4 specify information on supplementary tests on the isolate and on quantitative susceptibility of the AMR test or guidelines used to perform this test, and are optional. The data definition of Tables 3 and 4 should be taken as a guideline, and does not need to be followed 100% strictly. Possible alterations that are accepted: Participating laboratories are free to use any of these variable names or code values, or use their own nomenclature providing they can provide correspondence with this data definition. The use of uppercase and lowercase characters in variable names and code values should be ignored, as everything will be converted to lowercase. 3
4 rules to avoid duplicate observations are defined for the data submitted by the laboratory; these will be implemented by IPH/NSIH during preparation of national EARS-Net data. AMR tests for which results are submitted need not be limited to the ones shown in Table 1; after conversion, IPH/NSIH will only keep the ones belonging to the requested combinations. A participating laboratory can submit its results on the AMR test level in horizontal format as opposed to the vertical manner of the data definition of Table 4. In such horizontal format, the AMR test results for a particular isolate will be displayed in columns side-by side (each column representing an AMR test), instead of as separate observations. Also, when submitting horizontal AMR test data, please make sure to indicate info on variable 37 ReferenceGuidelinesSIR separately should a particular AMR test not follow EUCAST guidelines. During preparation of national EARS-Net data, IPH/NSIH will try to merge the AMR test data from a local laboratory with the data provided by the national reference laboratory and done on the same sample isolate. To make this possible, the local and reference laboratories need to submit EARS-Net data in which identifiers of exchanged isolates are constructed exactly the same; these are variables Patient ID (variable 11) and Isolate ID (variable 14). Furthermore, the national reference laboratory needs to submit EARS-Net data containing a clear identifier of the local laboratory (variable 7) providing each sample. Submitting EARS-Net data for 2016 and further treatment of data Data needs to be submitted to IPH/NSIH in the form of a flat-text data file, in Comma Separated Value (CSV) format or similar. If MS Excel is used, the use formatting such as calculated fields or hiding of columns or rows should be avoided. Submitting EARS-Net data proceeds by sending an with attachment to nsihdata@wiv-isp.be. Please make sure to indicate the full laboratory name and address in the mail message. A laboratory that tested zero isolates in 2016 for a particular pathogens or series of pathogens (with no resulting AMR data), is invited to report this in the mail message as well. Deadline for submitting EARS-Net data for 2016 is 16/5/2017. External Quality Assessment (EQA) All laboratories reporting data to EARS-Net will be invited to participate in the annual EQA. This is a service contracted by ECDC with United Kingdom National External Quality Assessment Service (UK NEQAS) at Public Health England. The annual procedure for this EQA is as follows: 4
5 UK NEQAS contacts the coordinator of EARS-Net BE at NSIH/IPH once a year, to update the contact details of participating laboratories and compile a final list of addresses of laboratories to be included in the EQA for BE. UK NEQAS then contacts the potential EQA participants with information on EQA reporting requirements and timelines, the provisions for intellectual property, data ownership and sharing, and planned post-eqa activities such as reports and publications. At the time of the actual EQA (most often early autumn), UK NEQAS prepares one package for each laboratory, containing a set of at least 6 bacterial isolates, safety instructions, and detailed information about routines for reporting of results. In addition to collection of EQA results, information on the use of methods (i.e. automated systems, disc diffusion, E-test etc.) and guidelines for clinical breakpoints as well as on the availability of and the requirement and/or obligation to participate to a national EQA scheme should be collected from the laboratories (type of EQA, mandatory, voluntary etc.). The packages (already labeled with the specific local laboratory address) are sent to the coordinator of EARS-Net BE. Laboratories register their results in an on-line database provided by UK NEQAS. The results will be compiled and analyzed by UK NEQAS, which will provide individual feed-back of the results to each participating laboratory; country reports to each national EQA coordinator providing all EQA results from the laboratories in the country. The report should include the results from all participating laboratories (including a national summary and results for each individual laboratory) and include a short conclusion on the capacity of participating laboratories and if needed, recommendations for improvement. Restrictions and confidentiality measures IPH/NSIH applies the same restrictions and confidentiality measures to EARS-Net data for 2016 of a particular laboratory and its contents as done with all other IPH/NSIH surveillances. This means that a particular laboratory s data (or its contents) will only serve the objectives stated in the EARS-Net protocol. When institute (laboratory or hospital)-specific results are reported or presented, the identity of a particular institute will be only disclosed to the designated contact person(s) of the institute itself. References Ref 1. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; ( ) 5
6 Ref 2. European Centre for Disease Prevention and Control. TESSy - The European Surveillance System. Antimicrobial resistance (AMR) reporting protocol Stockholm: ECDC; ( ) Ref 3. European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines and breakpoints to determine clinical antimicrobial susceptibility (available at ). 6
7 Table 1: Microorganism, specimen source and antimicrobial agent combinations under surveillance by EARS-Net Microorganism Specimen source Antimicrobial agent Streptococcus pneumoniae (STRPNE) blood (BLOOD); cerebrospinal fluid (CSF) Azithromycin (AZM) Cefotaxime (CTX) Ceftriaxone (CRO) Clarithromycin (CLR) Erythromycin (ERY) Levofloxacin (LVX) Moxifloxacin (MFX) rfloxacin (NOR) Oxacillin (OXA) Penicillin (PEN) Staphylococcus aureus (STAAUR) blood (BLOOD) Cefoxitin (FOX) Cloxacillin (CLO) Ciprofloxacin (CIP) Daptomycin (DAP) Dicloxacillin (DIC) Flucloxacillin (FLC) Levofloxacin (LVX) Linezolid (LNZ) Meticillin (MET) rfloxacin (NOR) Ofloxacin (OFX) Oxacillin (OXA) Rifampin (RIF) Vancomycin (VAN) Enterococcus faecalis (ENCFAE) blood (BLOOD) Ampicillin (AMP) Amoxicillin (AMX) Gentamicin-High (GEH) Linezolid (LNZ) Teicoplanin (TEC) Vancomycin (VAN) Enterococcus faecium (ENCFAI) blood (BLOOD) Ampicillin (AMP) Amoxicillin (AMX) Gentamicin-High (GEH) Linezolid (LNZ) Teicoplanin (TEC) Vancomycin (VAN) Escherichia coli (ESCCOL) blood (BLOOD); cerebrospinal fluid (CSF) Amikacin (AMK) Amoxicillin-clavulanic acid (AMC) Ampicillin (AMP) Amoxicillin (AMX) Cefepime (FEP)* Cefotaxime (CTX) Ceftazidime (CAZ) Ceftriaxone (CRO) Ciprofloxacin (CIP) Colistin (COL) Ertapenem (ERT) Gentamicin (GEN) Imipenem (IPM) Levofloxacin (LVX) Meropenem (MEM) Moxifloxacin (MFX) Netilmicin (NET) rfloxacin (NOR) Ofloxacin (OFX) Piperacillin-tazobactam (TZP) Polymyxin B (POL) Tigecycline (TCG) 7
8 Microorganism Specimen source Antimicrobial agent Tobramycin (TOB) Klebsiella pneumoniae (KLEPNE) blood (BLOOD); cerebrospinal fluid (CSF) Amikacin (AMK) Amoxicillin-clavulanic acid (AMC) Cefepime (FEP) Cefotaxime (CTX) Ceftazidime (CAZ) Ceftriaxone (CRO) Ciprofloxacin (CIP) Colistin (COL) Ertapenem (ERT) Gentamicin (GEN) Imipenem (IPM) Levofloxacin (LVX) Meropenem (MEM) Moxifloxacin (MFX) Netilmicin (NET) rfloxacin (NOR) Ofloxacin (OFX) Piperacillin-tazobactam (TZP) Polymyxin B (POL) Tigecycline (TCG) Tobramycin (TOB) Pseudomonas aeruginosa (PSEAER) Acinetobacter spp. (ACISPP) blood (BLOOD); cerebrospinal fluid (CSF) blood (BLOOD); cerebrospinal fluid (CSF) Amikacin (AMK) Cefepime (FEP) Ceftazidime (CAZ) Ciprofloxacin (CIP) Colistin (COL) Gentamicin (GEN) Imipenem (IPM) Levofloxacin (LVX) Meropenem (MEM) Netilmicin (NET) Piperacillin (PIP) Piperacillin/Tazobactam (TZP) Polymyxin B (POL) Tobramycin (TOB) Amikacin (AMK) Ciprofloxacin (CIP) Colistin (COL) Gentamicin (GEN) Imipenem (IPM) Levofloxacin (LVX) Meropenem (MEM) Netilmicin (NET) Polymyxin B (POL) Tobramycin (TOB) 8
9 Table 2: Microorganism and antimicrobial group combinations under regular EARS-Net surveillance Microorganism Antimicrobial group Antimicrobial agents Escherichia coli (ESCCOL) Aminopenicillins AMX, AMP Fluoroquinolones CIP, OFX, LVX, MFX, NOR Third-generation cephalosporins CTX, CRO, CAZ Aminoglycosides GEN, TOB, NET Carbapenems IPM, MEM Polymyxins POL, COL Klebsiella pneumoniae (KLEPNE) Fluoroquinolones CIP, OFX, LVX, MFX,NOR Third-generation cephalosporins CTX, CRO, CAZ Aminoglycosides GEN, TOB, NET Carbapenems IPM, MEM Polymyxins POL, COL Pseudomonas aeruginosa Piperacillin-tazobactam TZP (PSEAER) Ceftazidime CAZ Fluoroquinolones CIP, LVX Aminoglycosides GEN, TOB, NET Carbapenems IPM, MEM Amikacin AMK Polymyxins POL, COL Acinetobacter spp (ACISPP) Fluoroquinolones CIP, LVX Aminoglycosides GEN, TOB, NET Carbapenems IPM, MEM Amikacin AMK Polymyxins POL, COL Streptococcus pneumoniae Penicillins PEN, OXA (STRPNE) Macrolides ERY, CLR, AZM Fluoroquinolones LVX, NOR, MFX Third-generation cephalosporins CTX, CRO Staphylococcus aureus (STAAUR) MRSA MET, OXA, FOX, FLC, CLO, DIC Rifampicin RIF Fluoroquinolones CIP, OFX, LVX, NOR Linezolid LNZ Vancomycin VAN Daptomycin DAP Enterococcus faecalis (ENCFAE) High-level aminoglycoside resistance GEH and Enterococcus faecium Vancomycin VAN (ENCFAI) Aminopenicillins AMX, AMP Teicoplanin TEC Linezolid LNZ 9
10 Table 3: Epidemiological variables at isolate level (variables in grey are mandatory) 7 SampleDate (SamplingDate) Date when sample was taken. This date should fall in Yes Date Exact date only, YYYY-MM-DD 9 - Laboratory (LabId) Laboratory code unique for each laboratory within the country, assigned by national EARS-Net coordinator within IPH te: this is not the IPH/NSIH hospital code; Contact the national EARS-Net coordinator within IPH if unknown. need to provide this code if fixed for the entire file, in this case please provide the code as part of the exchange For data submitted by a national reference laboratory: this is the code of the local laboratory that provided the sample. Yes d Value 10 - Specimen (SampleType) Isolate source The source of the isolate (i.e. blood) Yes. d Value Enter data corresponding to the requested combination of Pathogen, Specimen and Antibiotic in Table 1 Microorganism, specimen source and antimicrobial agent combinations under surveillance by EARS-Net. BLOOD = blood CSF = Cerebrospinal fluid 11 PatientId used by the lab to specify patient. te: this code identifies the patient, not the admission within a hospital. Upon processing by IPH/NSIH, this code will be converted to an anonymous (patientcounter) numeric code. Yes Text 12 - Gender Gender, but recommended d Value M = Male F = Female O = Other UNK = Unknown 13 - Age (DateBirth) Age of the patient when the sample was taken, Alternatively, provide that patient s birth date. 10
11 , but recommended Numeric Integer 14 IsolateId Isolate ID; for each isolate, unique within lab and year Text code assigned by lab to specify isolate, but recommended Text 15 Hospital Identifier for the hospital where the sample was taken. Use a national hospital code (NSIH or RIZIV/INAMI for example), or simply the name of the hospital if unknown. te: this is not the laboratory code!, but recommended Text 16 - PatientType (AdmissionType) Origin of patient. Is the patient at the moment the sample is taken admitted in a hospital (inpatient), or not (outpatient). Patients that go to the hospital for Dialysis, other Day Hospital Care and to Emergency room should be classified as O for the field PatientType. All other patient that are admitted in the hospital as inpatients should be classified as INPAT., but recommended d Value INPAT= Admitted (Inpatient) OUTPAT= Outpatient O =Other (e.g. emergency room) UNK=Unknown 17 - HospitalUnitType Hospital department (at time of sample collection), but recommended d Value INTMED =Internal Medicine PEDS =Paediatrics/neonatal PEDSICU=Paediatrics/neonatal ICU SURG =Surgery ONCOL=Haematology/Oncology OBGYN=Obstetrics/Gynaecology ICU=Intensive Care Unit ED=Emergency Department URO=Urology Ward INFECT=Infectious Disease Ward O =Other UNK=Unknown 18 - Pathogen Pathogen Species and genus of the pathogen which has been isolated from the sample. Yes 11
12 Validation rule Validation rule Validation rule Validation rule d Value Provide data corresponding to the requested combination of Pathogen, Specimen and Antibiotic of Table 1 Microorganism, specimen source and antimicrobial agent combinations under surveillance by EARS-Net. STRPNE=Streptococcus pneumoniae STAAUR=Staphylococcus aureus ENCFAE=Enterococcus faecalis ENCFAI=Enterococcus faecium ESCCOL=Escherichia coli KLEPNE=Klebsiella pneumoniae PSEAER=Pseudomonas aeruginosa ACISPP=Acinetobacter spp DateOfHospitalisation (AdmissionDate) Date of admission in hospital Date Exact date only, YYYY-MM-DD 20 - ResultPCRmec Detection of PCR meca-gene d Value POS=positive NEG=negative UNK=unknown To be reported only if Pathogen=STAAUR ResultPbp2aAggl Detection of PBP2a-agglutination d Value POS=positive; NEG=negative; UNK=unknown To be reported only if Pathogen=STAAUR Serotype Serotype/group of the pathogen isolated from the sample. Reference: Danish Kauffman-Lund scheme from the WHO Collaborating Centre for Reference and Research on Pneumococci at the Danish Serum Institute. d Value Contact the national EARSNet BE coordinator within IPH/NSIH for a detailed list of codes To be reported only if Pathogen=STRPNE ESBL Detection of ESBL d Value POS=positive NEG=negative UNK=unknown To be reported only if Pathogen= ESCCOL or KLEPNE ResultCarbapenemases Detection of Carbapenemases. This refers to phenotypic test for carbapenemase activity (e.g. the Modified Hodge Test - MHT). 12
13 Validation rule d Value POS=positive NEG=negative UNK=unknown To be reported only if Pathogen= ESCCOL or KLEPNE or PSEAER or ACISPP 13
14 Table 4: Epidemiological variables at AMR test level (variables in grey are mandatory) 25 - Antibiotic (AntibioticECDC) Antimicrobial code Yes d Value, Provide data corresponding to the requested combination of Pathogen, Specimen and Antibiotic of Table 1 Microorganism, specimen source and antimicrobial agent combinations under surveillance by EARS-Net SIR (TestResult) Final interpretation result of all different susceptibility tests performed Yes d Value S=susceptible; I=intermediate; R=resistant 27 - ResultZoneSign Zone test operator (> < =). This field can indicate if a value of the zone diameter of the disk test is less than" (<); equal to or less than (< =); "equal to" (=); equal to or greater than (>=); or "greater than" (>) the value indicated in the following field. d Value < <= = >= > 28 - ResultZoneValue Zone test Value in mm. Numeric Integer 29 - ResultZoneSIR Zone test interpretation. d Value S=susceptible; I=intermediate; R=resistant 30 - ResultMICSign MIC test operator (> < =). type < <= = >= This field can indicate if a value of the zone diameter of the MIC test is less than" (<); equal to or less than (< =); "equal to" (=); equal to or greater than (>=); or "greater than" (>) the value indicated in the following field. d Value 14
15 > 31 - ResultMICValue MIC test value in mg/l. Text If <1 then float, if >=1 then integer 32 - ResultMICSIR MIC test interpretation. d Value S=susceptible; I=intermediate; R=resistant 33 - ResultEtestSign Gradient strip test operator (> < =). This field can indicate if a value of the zone diameter of the gradient strip is less than" (<); equal to or less than (< =); "equal to" (=); equal to or greater than (>=); or "greater than" (>) the value indicated in the following field. d Value < <= = >= > 34 - ResultEtestValue Gradient strip test value (Value in mg/l). Text If <1 then float, if >=1 then integer. The value 1.5 is also allowed ResultEtestSIR Gradient strip test interpretation. d Value S=susceptible; I=intermediate; R=resistant 36 - DiskLoad Disk content (only if Zone test). This field can be used to mention the load of the antimicrobial disk used. Please mention the value and the Units (e.g. mcg, Units or IU). Text Value and units: i.e. UI, mcg ReferenceGuidelinesSIR To differentiate use of CSLI and EUCAST guidelines for determining clinical breakpoint for antimicrobial susceptibility of the isolate 15
16 d value EUCAST = European Committee on Antimicrobial Susceptibility Testing CLSI = Clinical and Laboratory Standards Institute NAT = National O = Other 16
Including data call, instructions for participating laboratories, data definition, reporting procedure.
EARS-Net Belgium 2016 - Protocol: Including data call, instructions for participating laboratories, data definition, reporting procedure. (version 7, 6/7/2017) Questions on this document can be directed
More informationAntimicrobial resistance (AMR) reporting protocol TESSy - The European Surveillance System
TESSy - The European Surveillance System Antimicrobial resistance (AMR) reporting protocol 2018 European Antimicrobial Resistance Surveillance Network (EARS-Net) surveillance data for 2017 February 2018
More informationAntimicrobial resistance (AMR) reporting protocol TESSy - The European Surveillance System
TESSy - The European Surveillance System Antimicrobial resistance (AMR) reporting protocol 2017 European Antimicrobial Resistance Surveillance Network (EARS-Net) surveillance data for 2016 May 2017 Contents
More informationEARS-Net REPORTING PROTOCOL. Version 2, 2012
EARS-Net REPORTING PROTOCOL Version 2, 2012 TABLE OF CONTENTS 1. INTRODUCTION... 3 1.1 Structure of TESSy... 4 1.2 Implementation of AMR case definitions for TESSy... 5 1.3 Objectives for AMR surveillance...
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationCanadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS
Canadian Nosocomial Infection Surveillance Program 2018 SURVEILLANCE FOR HEALTHCARE ACQUIRED CEREBROSPINAL FLUID SHUNT ASSOCIATED INFECTIONS FINAL November 29, 2017 Working Group: Joanne Langley (Chair),
More informationEUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationMain objectives of the EURL EQAS s
EQAS Enterococci, Staphylococci and E. coli EURL workshop, April, 11 Lourdes García Migura Main objectives of the EURL EQAS s To improve the comparability of antimicrobial susceptibility testing (AST)
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationTECHNICAL REPORT External quality assessment of laboratory performance European Antimicrobial Resistance Surveillance Network (EARS-Net), 2017
TECHNICAL REPORT External quality assessment of laboratory performance European Antimicrobial Resistance Surveillance Network (EARS-Net), 2017 www.ecdc.europa.eu ECDC TECHNICAL REPORT External quality
More informationRCH antibiotic susceptibility data
RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More information9.4 Antimicrobial Resistance
9.4 Antimicrobial Resistance a) Key Pathogens causing Bloodstream Infections 2016 Summary Estimated 99% coverage of the Irish population versus 97% in 2015 There were 3,057 reports of invasive E. coli
More informationIntroduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.
Secondary Care Data Validation: What do commissioners need to know? Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2014 Introduction Antimicrobial
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More information9.5 Antimicrobial Resistance
9.5 Antimicrobial Resistance Key Points In 215, there was a slight reduction in coverage of the Irish population by EARS-Net versus 214, from 1% to 97% There were 2,697 reports of invasive Escherichia
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationESCMID Online Lecture Library. by author
Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More informationPROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains
PROTOCOL for serotyping and antimicrobial susceptibility testing of Salmonella test strains 1 INTRODUCTION... 1 2 OBJECTIVES... 2 3 OUTLINE OF THE EQAS 2017... 2 3.1 Shipping, receipt and storage of strains...
More informationESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationNon-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,
Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC
More informationSMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...
SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More informationAntimicrobial Resistance Surveillance from sentinel public hospitals, South Africa, 2013
Antimicrobial Resistance Surveillance from sentinel public s, South Africa, 213 Authors: Olga Perovic 1,2, Melony Fortuin-de Smidt 1, and Verushka Chetty 1 1 National Institute for Communicable Diseases
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationAntibacterial Resistance In Wales
A Report from Public Health Wales Antimicrobial Resistance Programme Surveillance Unit: Antibacterial Resistance In Wales 2005-2012 Authors: Maggie Heginbothom Robin Howe & Catherine Thomas Version: 1
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationInterpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes
Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes Prof C. Wattal Hon. Sr. Consultant & Chairman Dept. of Clinical Microbiology Sir Ganga Ram Hospital New Delhi
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More information1 INTRODUCTION OBJECTIVES OUTLINE OF THE SALM/CAMP EQAS
PROTOCOL For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 1 INTRODUCTION... 1 2 OBJECTIVES...
More informationANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014
ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 Olga Perovic, 1,2 Verushka Chetty 1 & Samantha Iyaloo 1 1 National Institute for Communicable Diseases, NHLS 2 Department
More informationStreptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance
Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter
More informationUNDERSTANDING YOUR DATA: THE ANTIBIOGRAM
UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Evansville, IN April.Abbott@Deaconess.com Special thanks to Dr. Shelley Miller for UCLA data WHAT WE WILL COVER
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationBACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)
BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationHUSRES Annual Report 2007 Martti Vaara.
HUSRES Annual Report 2007 Martti Vaara www.huslab.fi www.intra.hus.fi The basis of this HUSRES 2007 report is the HUSLAB/Whonet database 2007, which contains susceptibility data on about 182.000 bacteria
More informationESCMID Online Lecture Library. by author
System for early warning and national surveillance of antimicrobial resistance! Gunnar Kahlmeter Clinical microbiology Växjö, Sweden Early warning for antimicrobial resistance Local level (laboratory uptake
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationAntimicrobial resistance (EARS-Net)
SURVEILLANCE REPORT Annual Epidemiological Report for 2014 Antimicrobial resistance (EARS-Net) Key facts Over the last four years (2011 to 2014), the percentages of Klebsiella pneumoniae resistant to fluoroquinolones,
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationSurveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler
Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationAntibacterial Resistance In Wales
A Report from Public Health Wales Antimicrobial Resistance Programme Surveillance Unit: Antibacterial Resistance In Wales 2005-2013 Authors: Maggie Heginbothom and Robin Howe Version: 1 Antibacterial Resistance
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationAntibiotic Usage Guidelines in Hospital
SUPPLEMENT TO JAPI december VOL. 58 51 Antibiotic Usage Guidelines in Hospital Camilla Rodrigues * Use of surveillance data information of Hospital antibiotic policy guidelines from Hinduja Hospital. The
More informationService Delivery and Safety Department World Health Organization, Headquarters
Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important
More informationMonitoring of antimicrobial resistance in Campylobacter EURL AR activities in framework of the new EU regulation Lina Cavaco
Monitoring of antimicrobial resistance in Campylobacter EURL AR activities in framework of the new EU regulation Lina Cavaco licav@food.dtu.dk 1 DTU Food, Technical University of Denmark Outline EURL-AR
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationTaiwan Surveillance of Antimicrobial Resistance (TSAR)
Taiwan Surveillance of Antimicrobial Resistance (TSAR) 2009 MIRL Symposium July 17, 2009 Tsai-Ling Yang Lauderdale ( ) Microbial Infections Reference Laboratory (MIRL) Division of Infectious Diseases,
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationEUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM)
EUCAST Subcommitee for Detection of Resistance Mechanisms (ESDReM) Christian G. Giske, MD/PhD Chairman of ESDReM Karolinska University Hospital and EUCAST ECCMID, 22 maj 2013 The background Guidance on
More informationAntimicrobial Stewardship/Statewide Antibiogram. Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services
Antimicrobial Stewardship/Statewide Antibiogram Felicia Matthews Senior Consultant, Pharmacy Specialty BD MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda CMS and JCAHO
More informationQuality assurance of antimicrobial susceptibility testing
Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly
More informationHow is Ireland performing on antibiotic prescribing?
European Antibiotic Awareness Campaign 2016 November Webinar Series on Antibiotic Prescribing How is Ireland performing on antibiotic prescribing? Dr Rob Cunney National Clinical Lead HCAI AMR Clinical
More informationTABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11
Policy #MI\ANTI\v23 Page 1 of 3 Section: Antimicrobial Susceptibility Testing Subject Title: Table of Contents Manual Issued by: LABORATORY MANAGER Original Date: January 10, 2000 Approved by: Laboratory
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationAntimicrobial Resistance Strains
Antimicrobial Resistance Strains Microbiologics offers a wide range of strains with characterized antimicrobial resistance mechanisms including: Extended-Spectrum β-lactamases (ESBLs) Carbapenamases Vancomycin-Resistant
More informationAntimicrobial susceptibility
Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationJean-Winoc Decousser 1*, Paul-Louis Woerther 1, Claude-James Soussy 1, Marguerite Fines-Guyon 2 and Michael J. Dowzicky 3
Decousser et al. Antimicrobial Resistance and Infection Control (2018) 7:68 https://doi.org/10.1186/s13756-018-0360-y RESEARCH Open Access The Tigecycline Evaluation and Surveillance Trial; assessment
More informationBacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching
More informationBSAC antimicrobial susceptibility
BSAC antimicrobial susceptibility testing - from Stokes to European harmonization to world? Derek Brown 23 March 2011 BSAC antimicrobial susceptibility testing ti pre-working Party BSAC meetings from the
More informationCONSUMPTION OF ANTIMICROBIAL DRUGS AND ANTIBIOTIC RESISTANCE IN PROBLEMATIC FOR HOSPITAL INFECTIOUS PATHOLOGY BACTERIA
Trakia Journal of Sciences, No 4, pp 338-342, 2013 Copyright 2013 Trakia University Available online at: http://www.uni-sz.bg ISSN 1313-7050 (print) ISSN 1313-3551 (online) Original Contribution CONSUMPTION
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More information